Head and neck cancer

Researchers are testing whether giving tislelizumab, albumin paclitaxel, and cisplatin before surgery, followed by standard treatment, works better than standard treatment alone for people with locally advanced oral squamous cell carcinoma. The trial enrolls 134 participants with…

This study tests whether adding cetuximab to standard immunotherapy (pembrolizumab) helps people with advanced head and neck cancer that has stopped responding to platinum chemotherapy live longer. About 158 adults with cancer that has returned or spread will receive either pembr…

This trial tests a new approach for people with solid tumors that have returned or not responded to standard treatments. The therapy uses the patient's own myeloid cells, a type of immune cell, which are genetically modified in a lab to produce a cancer-fighting protein called IL…

This trial is testing a new drug called DS1025a in people with advanced solid tumors that have spread, cannot be removed by surgery, or have stopped responding to other treatments. The main goals are to check the drug's safety, how the body processes it, and whether it shows any …

This early-stage trial tests an experimental drug called STRO-006 in adults with advanced solid tumors, including head and neck, lung, esophageal, gastric, colorectal, endometrial, bladder, and breast cancers that have not responded to standard treatments. The study has three par…

This phase II trial is testing whether the combination of cabozantinib (a targeted therapy) and nivolumab (an immunotherapy) can shrink or stabilize advanced melanoma and head and neck cancers that have stopped responding to prior immunotherapy. Researchers are also checking if t…

This phase II trial is testing whether newer targeted drugs (trastuzumab emtansine and trastuzumab deruxtecan) work better than standard chemotherapy plus trastuzumab for people with HER2-positive or HER2-low salivary gland cancer that has come back, spread, or cannot be removed.…

This study tests a new drug called SX-682 (a tablet) combined with the chemotherapy docetaxel in people whose head/neck, salivary gland, or prostate cancer has spread or returned after treatment. The goal is to find the right dose and see if the combination shrinks tumors. About …

This early-phase trial tests a new drug called STC-15, either alone or combined with an immunotherapy drug (toripalimab), in people with advanced solid tumors or certain sarcomas. The study aims to check safety and whether the drugs shrink tumors. About 107 participants will be e…

This early-phase study tests a new drug called ARC101 in 70 people with advanced solid tumors that have a specific marker (Claudin 6). The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. Participants must have ovarian, testicular, or ot…

This early-stage trial tests a new drug called LY4052031, which is designed to deliver a cancer-killing agent directly to tumor cells that have a protein called Nectin-4. The study includes 420 adults with advanced or metastatic solid tumors such as bladder, breast, lung, and oth…

This Phase 2 trial tests whether adding fianlimab to cemiplimab works better than cemiplimab alone for people with advanced head and neck cancer that has come back or spread. About 120 participants whose tumors have a specific marker (PD-L1 positive) will receive either the drug …

This phase II trial is testing whether the immunotherapy drug pembrolizumab (Keytruda) alone can work better than the usual combination of chemotherapy and radiation after surgery for head and neck cancer that has come back or is a new primary tumor. About 188 adults aged 18-79 w…

This phase II trial tests whether adding the immunotherapy drug relatlimab to standard nivolumab maintenance therapy can extend the time before cancer grows or spreads in patients with recurrent or metastatic nasopharyngeal cancer linked to Epstein-Barr virus. Participants first …

This study tests an experimental drug called BMS-986482, alone or combined with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 413 adults will take part. Th…

This study tests an experimental drug called DB-1311/BNT324 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 862 adults will take pa…

This study tests an experimental drug, REGN7508, to see if it works better than the standard blood thinner apixaban for treating and preventing blood clots in people with cancer. The trial will include about 1,600 participants with or without cancer who have deep vein thrombosis …

This early-stage trial tests a new drug called CMAB017 in 55 people with advanced solid tumors (like head and neck cancer or colorectal cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see how the body…

This early-stage trial tests an investigational drug called CBX-663 in adults with certain advanced cancers that have not responded to standard treatment or have returned. The study includes people with blood cancers (like AML, MDS, or CMML), advanced solid tumors, or a type of b…

This study tests a new drug called TNG456, alone or with another drug (abemaciclib), in people with advanced cancers that have lost a gene called MTAP. The trial has two parts: first finding a safe dose, then testing how well it shrinks tumors. Up to 191 adults with lung cancer, …

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy can help control advanced solid tumors that have spread. About 115 adults whose cancer has worsened after at least one prior treatment will receive the combination. The main goal is to chec…

This study tests a new drug called HYP-6589, alone or with other cancer drugs, in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if the drug is safe and shrinks tumors. About 115 adults aged 18–80 with certain genetic marker…

This trial tests a new drug called N17350, a modified enzyme injected directly into tumors, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find the safest and most effective dose, and to see if the drug can shrink or stop tu…

This phase II trial is testing whether three antibody-drug conjugates (ADCs) can shrink advanced or metastatic solid tumors that have high levels of specific proteins (Trop-2, nectin-4, or HER2). About 500 patients will first have their tumors tested for these markers, then recei…

Researchers are testing YB1-X7, an engineered Salmonella bacteria designed to collect in oxygen-starved tumor tissue and release a payload that kills cancer cells. The trial enrolls adults with advanced or metastatic solid tumors that have not responded to standard treatment or l…

This trial is testing an experimental drug called petosemtamab (MCLA-158) in people with advanced solid tumors, including colorectal, head and neck, and lung cancers. The drug is a bispecific antibody designed to block two cancer-related proteins, EGFR and LGR5. Researchers want …

This study tests an oral drug called zongertinib in adults with advanced solid tumors that have HER2 mutations or overexpression and have not responded to prior treatment. Participants take one of two daily doses and continue as long as they benefit. Doctors regularly check tumor…

This early-stage trial is testing a new drug called BGB-58067, alone or with other cancer treatments, in people with advanced solid tumors that have a specific genetic change (MTAP deficiency). The study aims to find the safest dose and see if the drug can shrink tumors. About 52…

This early-stage trial tests a new drug called M7437 in people with advanced solid tumors that have not responded to standard treatments. M7437 is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells that have a specific marker (Ly6E). The study ai…

Researchers are testing whether two immunotherapy drugs, iparomlimab and tuvonralimab, combined with cetuximab can shrink locally advanced oral squamous cell carcinoma before surgery. The trial enrolls adults with resectable stage III to IVa disease. Participants receive three cy…

This study tests an experimental oral drug called FMC-376 in people with advanced solid tumors (like lung, colorectal, or pancreatic cancer) that have a specific genetic change called KRAS G12C. The trial has three parts: first, finding the safest dose; then, checking how well th…

This study tests a new oral drug called ART6043, alone or with another drug (olaparib), in 181 people with advanced or metastatic solid tumors. The goal is to check safety, how the body processes the drug, and whether it can slow tumor growth. It is an early-stage trial, so the m…

This study tests whether text-based support can help rural cancer survivors who smoke to quit. Participants will either receive text messages that gradually reduce cigarette use or a self-help manual. The goal is to see which approach works better for long-term smoking cessation.

This phase 2 trial is testing whether combining the immunotherapy drug pembrolizumab with a short course of high-dose radiation, with or without additional radiation to nearby lymph nodes, can shrink or eliminate head and neck tumors before surgery. Adults with resectable squamou…

This study is testing a new experimental drug called GI-101, given alone or with pembrolizumab or lenvatinib, in people with advanced or metastatic solid tumors (cancers that have spread). The goal is to see if the drug is safe and can shrink or control tumors. About 317 adults w…

This early-phase trial tests a new drug called Aza-TdC in adults with advanced solid tumors that have worsened after standard treatment or have no effective therapy. The drug is taken by mouth in 21-day cycles and aims to reactivate genes that may slow tumor growth. The main goal…

This study gives people who are already benefiting from the cancer drugs encorafenib and/or binimetinib in earlier trials continued access to these medicines for up to 5 years. It includes safety monitoring and is open to about 46 participants whose doctors confirm they are still…

This phase 2 trial is testing a combination of three therapies—modified immune cells (PD-L1 t-haNK), an immune-boosting protein (NAI/Anktiva), and a targeted antibody (cetuximab)—in 25 people with recurrent or metastatic head and neck cancer that has not responded to prior immuno…

This phase 2 trial tests whether adding an experimental vaccine (PRGN-2009) to standard chemotherapy can improve outcomes for people with newly diagnosed HPV-related throat cancer, potentially allowing them to skip radiation. About 70 adults will receive either chemo alone or che…

This study tests a new drug called LCB02A for people with advanced solid tumors that have a specific marker (CLDN18.2) and haven't responded to standard treatments. The drug is designed to deliver a toxin directly to cancer cells. The trial has two phases: first, finding the safe…

This study tests an experimental oral drug called NTS071 in adults with advanced solid tumors that have a specific change in the TP53 gene (Y220C mutation). The trial has two parts: first, finding a safe dose, and then checking if the drug can shrink tumors. About 220 people who …

This Phase 2 trial is testing whether a combination of two drugs, SYS6010 and Enlonstobart, can shrink tumors or slow the growth of head and neck cancer that has come back or spread. About 70 adults aged 18-75 who have not had prior systemic treatment for their advanced cancer wi…

Researchers are running a Phase I trial of BA1203, an experimental drug given intravenously every two weeks, in adults with advanced solid tumors that have worsened after standard treatments. The study aims to find out whether BA1203 is safe and tolerable, how the body processes …

This study tests a two-step treatment for people whose nasopharyngeal cancer has come back after initial treatment. First, patients receive a targeted drug (MRG003) plus an immunotherapy (PD-1) for six weeks. Then, they take a chemotherapy pill (capecitabine) with the immunothera…

This phase 2 trial tests whether adding the immunotherapy drug toripalimab to standard chemotherapy (cisplatin and docetaxel) is safe and tolerable as an initial treatment for people with advanced head and neck cancer. The study enrolls 26 adults whose tumors have a certain prote…

This phase 1 trial tests an experimental drug called TJ037130 in adults with advanced solid tumors, including ovarian, gastric, and endometrial cancers that have spread. The main goal is to check the drug's safety and find the best dose for future studies. Participants receive TJ…

This phase 1 study tests a combination of two drugs, pomalidomide (a pill) and nivolumab (an infusion), in adults with cancers caused by viruses like Epstein-Barr, HPV, or hepatitis. The goal is to find a safe dose and see if the drugs can shrink tumors. Up to 58 people with Kapo…

This phase 2 trial is testing whether adding an investigational drug called telisotuzumab adizutecan to the standard immunotherapy pembrolizumab can better control recurrent or metastatic head and neck squamous cell carcinoma. The study enrolls adults whose tumors express a speci…

This phase 2 trial tests enasidenib, a daily pill that targets the IDH2 gene mutation, in 40 adults with rare cancers of the nasal cavity or skull base that have spread or come back. Participants take the drug once daily in 28-day cycles, and researchers will track how long the c…

Researchers are testing a new targeted radioligand therapy called [225Ac]Ac-FL-261 in people with advanced solid tumors that overexpress a protein called c-MET. The therapy pairs a radioactive particle with a molecule that seeks out c-MET, aiming to deliver radiation directly to …

This early-stage trial tests an investigational drug called ABBV-253 in adults with advanced solid tumors, including lung, colorectal, and pancreatic cancers. The study aims to find safe doses and see whether the drug can shrink tumors. Participants receive the drug by infusion, …

This study tests an experimental drug called ATX-898 in people with advanced solid tumors that have spread or cannot be removed by surgery. The trial has two parts: first, ATX-898 is given alone to find the safest dose; second, it is combined with other anti-cancer drugs to see i…

This phase 2 trial is testing whether adding the immunotherapy drug toripalimab to standard chemotherapy can help people with advanced laryngeal or hypopharyngeal cancer avoid having their voice box removed. The study will enroll 87 adults whose cancer has not been treated before…

Researchers are testing an experimental oral drug called XNW29016 in adults with advanced solid tumors that have not responded to standard treatment. The trial has two parts: a dose-escalation phase to find a safe dose and a dose-expansion phase to look at early signs of activity…

This study tests whether adding an experimental drug (CDX-1140) to a standard immunotherapy (cemiplimab) before surgery can shrink advanced head and neck cancers more than the immunotherapy alone. About 44 people with stage III-IV head and neck cancer will receive either the comb…

This early-phase trial tests a new drug called metarrestin in people with advanced solid tumors that have spread (metastasized). The goal is to find a safe dose and see if it can shrink tumors. The study includes adults with pancreatic, breast, or other solid tumors, and children…

This study tests an experimental drug called JAB-23E73, taken as a pill, in adults with advanced solid tumors that have a KRAS alteration. The trial has three parts: first finding a safe dose, then optimizing it, and finally checking if the drug shrinks tumors in certain cancers …

This study tests a new drug called AVZO-1418 in people with advanced solid tumors that have spread. The goal is to find a safe dose and see if it shrinks tumors. About 480 adults will take part, receiving the drug alone or with other treatments.

This study tests a vaccine made from candida (a type of yeast) to see if it can reduce the risk of head and neck cancer coming back. About 100 adults who have finished cancer treatment and are currently cancer-free will receive either the vaccine or a placebo over two years. The …

This early-phase study tests CBX-12 in about 35 adults with advanced solid tumors that have spread and stopped responding to prior treatments. CBX-12 works by entering cancer cells and damaging their DNA, which can kill the cells. Researchers will measure how well the drug trigge…

This study tests an experimental drug called SMP-3124LP, which is a liposomal (fat-encapsulated) version of a cancer-fighting compound. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding the safest d…

This study tests a new drug called MDX2001 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety and see if it can shrink tumors. About 285 adults with various cancers like lung, breast, or colon cancer will take part. This is an ear…

This phase 2 trial is testing whether combining an experimental immunotherapy (MK-2010) with an antibody-drug conjugate (sacituzumab tirumotecan) can help people with advanced solid tumors. The goal is to see if the combination is safe and can shrink or eliminate tumors. Particip…

This early-phase trial tests an experimental drug called BSI-082, alone or combined with a standard cancer drug (T-DXd), in 57 adults with advanced or metastatic solid tumors that have not responded to other treatments. The study has two parts: first, finding the safest dose of B…

This early-phase study tests a new drug called DS-3939a in about 540 people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety and see if the drug shrinks tumors. Participants must have measurable disease and good organ function.

This early study tests an experimental drug called XB010, alone or combined with the immunotherapy pembrolizumab, in people with advanced solid tumors (like lung, breast, or head and neck cancers) that have stopped responding to other treatments. The main goals are to find a safe…

This early-phase study tests a new drug called EPI-326 in about 110 people with advanced lung or head & neck cancers that have specific EGFR mutations. The drug is a bispecific antibody designed to target cancer cells more precisely. The main goals are to check safety, find the r…

This phase 2 trial is testing whether a combination of lenvatinib (a targeted drug) and a PD-1 inhibitor (immunotherapy) can shrink or stop advanced solid tumors that have a specific genetic change called 11q13 amplification. About 60 adults with various cancers like esophageal, …

This study compares a newer, precise radiation method called stereotactic body radiotherapy (SBRT) with standard radiation therapy for people with advanced head and neck cancer who cannot have curative treatment. About 196 adults will be randomly assigned to one of the two radiat…

Researchers are testing a new biological therapy called BI 4060107 in adults with advanced solid tumors that cannot be removed by surgery. The trial is for people who have tried all available treatments and have no other options. The main goal is to find the highest dose that peo…

This phase II trial is testing whether adding a type of precise radiation called stereotactic body radiation therapy (SBRT) to standard immunotherapy can help people with stage IV cancers, including head and neck, lung, cervical, esophageal, and gastric cancers. Participants will…

This study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy (gemcitabine and cisplatin) before radiation therapy is safe and effective for children and young adults (up to age 21) with newly diagnosed nasopharyngeal carcinoma. The goal is to see if t…

This phase 2 trial is testing whether adding a special type of radiation called adaptive pulse radiotherapy to standard immunotherapy can help treat advanced solid tumors. The study will enroll 35 people who are already receiving or planning to receive immune checkpoint inhibitor…

This Phase 1 trial tests MST-168, an antibody-drug conjugate designed to target and kill cancer cells. It will enroll 420 adults with advanced solid tumors that have specific markers. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage.

This trial compares two treatments for advanced head and neck squamous cell carcinoma. One group receives standard chemoradiation, which combines radiation with the chemotherapy drug cisplatin. The other group receives hyperfractionated radiation, which delivers a higher total do…

This study tests a new medicine called TAK-188 in adults with advanced solid tumors that have not improved with standard treatments. TAK-188 targets and removes certain cells inside tumors that weaken the immune system, potentially allowing the body to better fight the cancer. Th…

This early-stage trial tests a new drug called KO-2806, alone or with other cancer drugs, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and check for early signs of tumor shrinkage. About 300 participants wi…

This early-phase trial tests an investigational drug called ABBV-400 in about 300 adults with advanced solid tumors, including liver, pancreatic, breast, and ovarian cancers. The study aims to see if the drug can shrink tumors and to check for side effects. Participants receive A…

This phase II trial is testing whether adding chemotherapy or chemo-immunotherapy before standard salvage surgery can improve outcomes for patients with PD-L1 positive head and neck cancer that has come back. About 180 participants will receive either carboplatin and paclitaxel, …

This early-phase study tests an experimental drug called PF-08046876 in about 310 adults with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas that have not responded to standard treatments. The drug is a type of 'antibody drug conjugate' designed to s…

This study tests a new drug called PM54 combined with the immunotherapy pembrolizumab in adults with advanced cancers that have not responded to prior treatments. The goal is to find a safe dose and see if the combination can shrink tumors or stop them from growing. About 119 par…

This study tests a new daily pill, ETX-636, for people with advanced solid tumors (including breast cancer) that have a specific genetic change called PIK3CA. The trial has two parts: first, finding a safe dose of ETX-636 alone or with another drug (fulvestrant); second, checking…

Researchers are running a first-in-human Phase I trial of AK157D1, an experimental drug given by intravenous infusion, in adults with advanced solid tumors that have worsened after standard treatment or have no standard options left. The study aims to find out whether the drug is…

This Phase 1 trial tests two experimental mRNA immunotherapies, mRNA-4106 and mRNA-4200, in about 42 people with advanced solid tumors. Unlike personalized cancer vaccines made from a patient's own tumor mutations, these are off-the-shelf therapies designed to target shared antig…

This early-stage study is testing an experimental drug called MK-6204 in about 90 adults with advanced solid tumors (such as colorectal, lung, or stomach cancer) that have not responded to standard therapies. The main goals are to check the drug's safety and find the right dose. …

Researchers are running a first-in-human Phase 1 trial of BA1106, an experimental intravenous drug, in adults with advanced solid tumors that have worsened after standard treatments. The main goal is to check safety and tolerability, and to see how the body processes the drug. Pa…

This phase 2 trial tests an experimental drug called ficerafusp alfa, which targets two proteins that help tumors grow, when given with the immunotherapy pembrolizumab. The study enrolls adults with recurrent or metastatic head and neck squamous cell carcinoma that has not been t…

Researchers are running a first-in-human Phase 1 trial of BA1302, an intravenous drug, in adults with advanced solid tumors including melanoma, breast cancer, non-small cell lung cancer, and pancreatic adenocarcinoma. The trial has two parts: a dose-escalation phase to find a saf…

Researchers are testing an engineered interleukin-2 drug called MDNA11 in adults with advanced solid tumors. The trial gives MDNA11 alone or with pembrolizumab, an immune checkpoint inhibitor, to see which doses are safe and how the body processes the drug. It also looks for earl…

This study tests a new drug called HY07121 in 258 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV infusion. The main goals are to check safety, find the right dose, and see if it can shrink tumors. This is an early-stage t…

Researchers are running a first-in-human Phase 1 trial of BA1301, an experimental drug given intravenously every three weeks, in adults with advanced solid tumors that cannot be removed by surgery. The trial enrolls about 70 people aged 18 to 75 whose cancer has progressed after …

This early-phase study tests a new targeted therapy called MK-8294 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety, see if people can tolerate it, and find the highest safe dose. About 67 participants will receive the drug, and…

This early-stage study is testing a new drug called AT03-65 in 83 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose, while also looking for early signs that the drug might shrink tumors. Part…

This early-phase trial tests a new drug called YKYY031 in 76 people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and get a first look at whether the …

This early-phase trial is testing a new drug called ASP5834 in people with advanced solid tumors that have certain changes in the KRAS gene. The study will first find a safe dose of ASP5834 given alone or with another drug (panitumumab) in people with colorectal cancer. Up to 364…

This study tests a new drug, BI 1703880, combined with ezabenlimab in adults with advanced solid tumors that haven't responded to other treatments. The main goal is to find a safe dose of BI 1703880. Participants receive both drugs as infusions, with BI 1703880 given weekly then …

This study looks at whether getting standard immunotherapy in the morning (before 11 am) or afternoon (after 12 pm) changes how well it fights advanced or metastatic solid tumors. Researchers think the body's internal clock (circadian rhythm) might affect immune activity. About 1…

This study tests whether giving radiation early to spine tumors that are not yet painful can prevent serious problems like fractures or spinal cord compression. About 74 adults with cancer that has spread to the spine will receive radiation before symptoms get worse. The goal is …

This early-stage trial tests an experimental medicine called BI 3822971 in adults with advanced or metastatic solid cancers, such as lung, head and neck, breast, esophageal, bladder, vulvar, or cervical cancer, who have no standard treatment options left. The goal is to find out …

This trial is testing an investigational drug called ARV-6723, given as a pill, in people with advanced solid tumors. The drug is designed to help the immune system recognize and attack cancer cells. The study will test ARV-6723 alone and in combination with pembrolizumab, an imm…

This study tests a new drug called MHB046C in 200 people with advanced solid tumors that no longer respond to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Participants receive the drug intravenously every three weeks.

This study tests whether a shorter, lower-dose course of radiation after robotic surgery can improve quality of life for people with HPV-related throat cancer. About 42 adults who have had robotic surgery will receive a reduced radiation schedule. The goal is to see if this appro…

Researchers are testing an experimental antibody injection called MHB118C in adults with advanced solid tumors that have not responded to standard treatments. The trial aims to find out whether the drug is safe, what side effects it causes, and what dose people can tolerate. Part…

This study tests a new drug called BNT326, given alone or with other cancer immunotherapies, in about 980 adults with advanced solid tumors that have spread or come back after prior treatment. The goal is to find the best dose and see if it is safe and effective. It is an early-s…

This early-phase trial tests two experimental drugs, MHB088C and MHB039A, given together by IV to people with advanced solid tumors that no longer respond to standard treatments. The study has two stages: first, finding the safest dose, then checking if the combination can shrink…

This study tests OTP-01, a new drug that targets two cancer pathways (PD-1 and VEGFR2) at once, in 170 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the best dose, check safety, and see if the drug can shrink tum…

This early-stage study tests a new drug, APX-343A, alone or with another cancer drug (pembrolizumab) in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Ab…

This early-stage study tests a new oral drug, APR-1051, in about 90 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety and find the right dose. Researchers will also look for early signs that the drug might…

This study tests the drug ponatinib in children aged 1 to 18 with advanced leukemias, lymphomas, or solid tumors that have come back or not responded to standard treatment. The goal is to find safe doses and see if the drug can shrink tumors or improve blood counts. About 70 chil…

This study tests an experimental drug called TRK-950 in people with advanced solid tumors or melanoma that has not responded to standard treatments. The first parts check safety and side effects when given alone or with another cancer drug (nivolumab). The final part looks at whe…

This study tests a new drug, AZD6750, that helps the immune system fight cancer. It is for adults with advanced solid tumors like melanoma, lung, or breast cancer that have not responded to other treatments. The goal is to find the safest dose and see if it shrinks tumors when us…

This Phase 2 trial tests a drug called belzupacap sarotalocan (AU-011) for people whose cancer has spread to the choroid, the layer of blood vessels in the eye. The drug is injected into the eye and then activated with a laser. The study aims to see if it is safe and can shrink o…

Researchers are testing whether a specialized radiation technique called lattice radiotherapy, combined with PD-1/PD-L1 inhibitor drugs, can safely shrink large tumors in people with advanced solid cancers. The trial enrolls adults whose cancer has progressed after standard treat…

This study tests whether giving less radiation to healthy lymph nodes can reduce side effects for people with oropharynx cancer. The approach uses a computer model to personalize which lymph nodes need treatment. The trial will enroll 120 patients and track if cancer returns in u…

This phase 1 trial tests a drug called 177Lu-DTPA-omburtamab, which delivers radiation directly to tumor cells in children and teens with recurrent or refractory medulloblastoma or other central nervous system (CNS) tumors that have spread. The drug targets a protein called B7-H3…

This trial is testing whether CRB-701, a targeted chemotherapy that delivers a potent drug directly to cancer cells, can shrink tumors and extend life in people with recurrent or metastatic oropharyngeal (throat or tonsil) cancer. Participants will have already tried platinum-bas…

This study tests a new drug that delivers a tiny dose of radiation directly to cancer cells that have a specific marker called FAP. The trial involves 112 adults with advanced cancers of the pancreas, stomach, esophagus, colon, ovary, head/neck, sarcoma, or mesothelioma. First, a…

This early-phase study is testing an experimental drug called 177Lu-IM-3050 in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. About 105 participants will receive the drug to s…

This trial tests whether repairing the facial vein during neck dissection can prevent lymphedema—painful swelling—in adults with head and neck cancer. Participants receive standard cancer surgery plus, if needed, immediate reconstruction of the facial vein. Researchers then compa…

This early-stage trial is testing an experimental drug called BMS-986500 in people with advanced solid tumors or breast cancer that has not responded to prior treatments. The study will first test the drug alone, then in combination with other cancer drugs (palbociclib and fulves…

This early-phase trial is testing a new type of radiation called HYDRA for people with laryngeal cancer. The goal is to find the highest safe dose and see how well it controls the tumor. Eleven participants will receive different doses of radiation and complete quality-of-life su…

This early-phase trial tests a new treatment made from specially engineered cord blood cells (TROP2-CAR-NK cells) in adults with advanced solid tumors that have not responded to standard therapies. The main goal is to find a safe dose and monitor side effects. Up to 54 participan…

This study tests whether a single infusion of a patient's own genetically engineered immune cells (E7 TCR-T cells) can shrink or eliminate HPV-related cancers before the patient receives standard treatment like chemo-radiation or surgery. The trial enrolls 15 adults with advanced…

This early-stage trial tests a radioactive drug that seeks out and delivers radiation directly to cancer cells with a specific protein (somatostatin receptor). It is for adults with advanced lung, kidney, head and neck, digestive tract, or adrenal gland tumors that cannot be remo…

This study is testing a new drug called MK-3120 in people with advanced solid tumors that have spread and cannot be removed by surgery. The main goal is to see if the drug is safe and tolerable. About 270 participants will receive the drug by IV infusion. The study also looks at …

This early-phase trial is testing a new drug called IACS-6274, either alone or combined with other cancer drugs, in 54 adults with advanced solid tumors (such as melanoma, ovarian, or head and neck cancers). The main goal is to find the safest dose and understand side effects. Th…

This study tests whether the antiviral drug letermovir can prevent cytomegalovirus (CMV) infection in children and teens who have had a stem cell transplant. About 105 participants aged 2 to 17 will receive letermovir and be monitored for 14 weeks. The goal is to see if the drug …

This trial investigates a new drug called GEN1119 for people with certain solid tumors that have not improved with standard treatments or for whom no standard treatment exists. The study is divided into parts: first, to find safe and effective doses, then to test those doses in m…

This phase 2 trial tests a drug called BMS-986504 in people with advanced solid tumors that have lost a gene called MTAP. The drug is given alone or with other cancer medicines. The study aims to see if the drug shrinks tumors and how safe it is. About 260 adults will take part.

Researchers are testing an experimental drug called BCA101 in people with advanced solid tumors that are driven by EGFR, a protein that helps cancer cells grow. BCA101 is a dual-targeting antibody designed to block both EGFR and TGF-beta, a signal that can suppress the immune sys…

This early-stage trial tests a new drug called SHR-4685 in people with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 170 adults aged 18 to 75 with meas…

This phase 2 study tests a drug called AZD2936 in people with high-risk head and neck cancer who still have traces of cancer DNA in their blood after completing standard treatment. The drug is designed to boost the immune system to find and destroy these remaining cancer cells. A…

Researchers are testing an experimental oral drug called T-1301 in people with advanced solid tumors or lymphoma that have not responded to standard treatments. The Phase I trial aims to find the highest dose participants can tolerate and the dose best suited for later studies. A…

This early-stage trial tests a new therapy made from cord blood immune cells that are engineered to better target and attack head and neck cancer cells. Up to 33 patients with advanced disease that has not responded to standard treatments will receive these cells along with low-d…

This study tests a new treatment called KSQ-004EX for people with advanced solid tumors that have not responded to standard therapies. The treatment uses a patient's own immune cells (tumor infiltrating lymphocytes) that are genetically modified to be more powerful against cancer…

This phase 2 trial tests whether adding the immunotherapy drug cemiplimab to standard chemotherapy before surgery helps people with sinonasal squamous cell carcinoma. About 108 participants will be randomly assigned to receive either chemo alone or chemo plus cemiplimab before th…

This early-phase trial is testing a new drug called PHST001, which helps the immune system attack cancer cells by blocking a protein called CD24. The study will first test PHST001 alone, then in combination with standard chemotherapy, in adults with advanced solid tumors (includi…

This study tests a new way to give the drug rilvegostomig as a shot under the skin instead of through an IV. It is for adults with advanced solid tumors who have already tried standard treatments. The goal is to find a dose that works as well as the IV version and to check for si…

This trial tests whether adding an experimental drug called Enlituo to a standard chemotherapy combination helps people with advanced, recurrent, or metastatic head and neck squamous cell carcinoma. Participants receive either the standard combination (Anyouping plus platinum-bas…

This trial is testing an experimental drug called ML-016, a nanoparticle form of the chemotherapy doxorubicin, in people with advanced solid tumors that have spread to the lungs or liver. The study aims to find the safest dose and see whether the drug can shrink tumors or slow th…

This early-stage study tests a new drug called casdatifan (AB521) alone or combined with other cancer drugs in people with advanced clear cell kidney cancer or other solid tumors. The main goals are to check safety and find the right dose. About 362 participants will take part.

This study tests whether adding ficerafusp alfa to the immunotherapy nivolumab can shrink tumors better than nivolumab alone in people with advanced head and neck cancer that has stopped responding to platinum chemotherapy. About 131 adults aged 18-75 will take part. The goal is …

This study is for people who have both an autoimmune disease (like rheumatoid arthritis, lupus, or multiple sclerosis) and an advanced cancer that has spread or cannot be removed by surgery. It tests the safety and effectiveness of the immunotherapy drug nivolumab, given alone or…

This study tests an experimental oral drug called GFH276 combined with either cetuximab or standard chemotherapy in people with advanced solid tumors or pancreatic ductal adenocarcinoma (PDAC) that have a RAS mutation. The goal is to see if the combination is safe, tolerable, and…

Researchers are testing an experimental intravenous drug called T-1201 in adults with advanced solid tumors that have not responded to standard therapy or have no standard treatment left. The main goals are to find the highest dose people can tolerate and the dose best suited for…

Doctors usually wait for biopsy results before giving radiation, but that wait can be long and painful for patients with advanced cancer. This trial tests whether giving palliative radiation first, before a biopsy confirms cancer, is safe and practical for a carefully selected gr…

This study gives people with cancer continued access to an experimental Roche treatment they were already receiving in a previous trial. It is for patients who still need the drug and cannot get it locally. The goal is to keep providing the treatment and monitor any side effects.

This study tests whether adding a targeted drug (cetuximab) to standard immunotherapy (pembrolizumab or finotonlimab) and chemotherapy helps people with advanced head and neck cancer live longer without their cancer growing. About 316 adults aged 18-70 with cancer that has spread…

This trial is testing an experimental therapy called STX-003, which uses mRNA to produce a protein that may help the immune system fight cancer. It is given intravenously, either alone or with the immunotherapy drug pembrolizumab (Keytruda). The study involves adults with advance…

This study tests a new drug called mocertatug rezetecan (Mo-Rez) combined with other cancer medicines for people with advanced solid tumors that have stopped responding to standard treatments. About 305 adults will join to see if the combination is safe, tolerable, and effective.…

This study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…

Researchers are testing an experimental oral drug called GH56 in people with advanced solid tumors that have lost the MTAP gene. The trial enrolls adults and adolescents whose cancer has progressed after standard treatment or who have no standard options left. The study first fin…

This study tests whether adding an experimental drug called ficerafusp alfa to the immunotherapy pembrolizumab (Keytruda) works better than pembrolizumab alone for people with PD-L1-positive head and neck cancer that has spread or returned. About 650 adults will be randomly assig…

This study is testing whether taking three oral chemotherapy drugs together is safe and practical for patients with head and neck cancer that has returned or spread. The trial focuses on people living in rural Midwest areas, making it easier for them to participate from home. The…

This early-stage trial tests an experimental drug called E303 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goals are to check safety and see if the …

This trial tests an experimental drug called HMPL-A830 in adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then testing that dose in more people to see if it can shrink tumors. The goal is to un…

Researchers are testing a new oral drug called HTL0039732 in people with advanced solid tumors that have not responded to standard treatments. The trial gives the drug alone and in combination with atezolizumab or other approved cancer therapies. The main goals are to find a safe…

This study tests an experimental drug, hetrombopag, to see if it can safely raise platelet counts in cancer patients whose platelets drop too low after chemotherapy. About 150 adults with solid tumors (like lung, breast, or colon cancer) will receive either the drug or a placebo …

This phase II trial tests whether a blood test that detects HPV DNA can help doctors decide the right amount of radiation for people with HPV-positive throat cancer. About 455 participants will either have surgery or receive standard chemotherapy plus radiation, but the radiation…

This study tested three flavors of Supportan® drink (Tropical Fruits, Cappuccino, and Pineapple-Coconut) in 123 cancer patients undergoing chemotherapy, radiotherapy, immunotherapy, or targeted therapy. Patients drank two bottles daily for four weeks alongside their normal diet. …

This early-phase study tests a new drug called 177LuBetaBart in people with advanced solid tumors that have stopped responding to standard treatments. The drug is a radioactive antibody designed to seek out and destroy cancer cells. The study will enroll about 61 participants and…

This phase 2 trial is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in 740 people with advanced solid tumors, including melanoma, lung, breast, and other cancers. The drug is given by IV every three weeks. The main goal is to see if the drug shrinks tumors.…

This phase 2 trial tests a new drug, GSK5764227, that delivers chemotherapy directly to cancer cells, either alone or with an immunotherapy called dostarlimab. The study enrolls 30 people with recurrent or metastatic head and neck cancer. Researchers will analyze tumor samples an…

This study tests a new drug called IPN60300 in adults with advanced solid tumors that have spread or not responded to standard treatments. The goal is to find the best dose and check if it is safe and shrinks tumors. All participants get the drug by injection, and the study invol…

This early-stage trial is testing an experimental drug called SI-B036, a bispecific antibody designed to target cancer cells in a unique way. The study involves adults with locally advanced or metastatic head and neck tumors or other solid tumors. The main goals are to assess the…

This study tests a new drug called zanzalintinib, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth.…

This early-phase trial tests a new type of immune cell therapy for people with advanced solid tumors that have not responded to standard treatments. The therapy uses a patient's own natural killer (NK) cells that have been genetically modified to produce IL-15, a protein that hel…

Researchers are testing a new drug called TS-104 in adults with advanced solid tumors, including lung, head and neck, ovarian, endometrial, esophageal, and gastric cancers. TS-104 is a peptide drug conjugate: it uses a targeting peptide to carry the chemotherapy drug MMAE directl…

This large Phase 3 trial tests whether an experimental immunotherapy drug called volrustomig can help prevent cancer from returning in people with locally advanced head and neck cancer who have finished chemoradiation. About 1,145 participants will either receive volrustomig or b…

This early-stage study is testing a new drug called ALX2004 in people with advanced lung, head and neck, esophageal, or colorectal cancers that have not responded to standard treatments. ALX2004 is an antibody-drug conjugate designed to deliver a cancer-killing payload directly t…

This early-stage study tests a new drug called FP008 in 108 adults with advanced solid tumors that have not responded to other treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look at how the drug works in the body and whether…

This study tests a drug called eflapegrastim in 40 children with solid tumors or lymphoma who are receiving chemotherapy. The drug aims to boost white blood cells and reduce the risk of serious infections. Researchers are checking how safe it is and how the body processes it.

This early-stage trial tests a new drug called JNJ-95437446 in people with advanced solid tumors, including colorectal cancer, that have not responded to standard treatments. The study has two parts: first, finding a safe dose, and second, checking safety more closely in a larger…

This early-phase trial is testing whether a new drug called ZEN003694, when added to the chemotherapy capecitabine, is safe for people with advanced solid tumors that have spread or can't be removed by surgery. About 30 participants will receive the combination to find the best d…

Researchers are testing a less intense chemoradiotherapy regimen for older adults with HPV-associated oropharynx cancer. Standard treatment uses high-dose radiation and chemotherapy, which can cause serious short- and long-term side effects. This pilot study gives 20 participants…

This early-phase trial is testing an experimental biologic drug, DBC-664, in adults with advanced solid tumors such as ovarian, lung, and stomach cancers that have spread or come back. The study has two parts: first, finding a safe dose, and then expanding to see how well the dru…

This study tests a combination of two drugs, nemtabrutinib and rituximab, in about 35 adults with marginal zone lymphoma, a slow-growing blood cancer. The goal is to see if the combo is safe and can shrink or eliminate tumors. Participants will receive the drugs by mouth and thro…

This early-stage study tests a new drug, AUBE00, in about 90 to 130 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants must have a spec…

This early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 is made from a patient's own immune cells, which are …

This trial tests whether a special dye called indocyanine green (ICG), injected during surgery, helps surgeons see blood flow in reconstructed tissue better than standard checks. About 244 adults having head and neck reconstruction will be randomly assigned to get the dye or stan…

This early-phase trial tests a new drug called BI 3810944 in adults with advanced solid tumours or melanoma who have no other treatment options. The study aims to find a safe and tolerable dose, and to see if the drug can shrink tumours. Participants receive the drug every three …

This study is testing a new experimental drug called BG-75098, given alone or with other medicines, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tum…

This early-phase study is testing a new drug called BGB-26808, either alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. About 217 partici…

This early-phase trial is testing a new drug called BG-C0902 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to attach to two proteins (EGFR and MET) often found on cancer cells and deliver a toxic payload directly to them…

This early-phase study tests a new drug called BG-C0979, alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…

This early-phase study is testing a new oral drug called BG-75202, alone or with other medications, in people with advanced breast cancer or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and …

This early-phase trial is testing a new drug called BHV-1510, either alone or with another drug (cemiplimab), in 500 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and see if the drug can shrink tumors. Because …

This study tests whether giving siltuximab alongside restarting immunotherapy can prevent severe immune-related side effects in people with advanced cancer. About 40 adults who previously had serious side effects from immunotherapy will receive siltuximab to calm the immune syste…

This early-phase trial tests a new drug called RPTR-1-201 in 150 adults with advanced solid tumors that cannot be cured with standard treatments. The drug works by helping the body's immune cells attack cancer. The study aims to find the safest dose and see if the drug shrinks tu…

This early-stage trial tests a new drug called HF50 in 45 adults with advanced solid tumors that have not responded to standard treatments. HF50 is designed to target HER2 on cancer cells and boost the immune system. The main goals are to check safety, find the right dose, and se…

This study tests a drug called amivantamab, either alone or combined with other cancer drugs (pembrolizumab, paclitaxel, carboplatin), in people with head and neck cancer that has spread or come back. The goal is to see if these treatments are safe and can shrink tumors. About 28…

This early-stage study is testing whether a new drug, JNJ-90301900, is safe and works when injected directly into tumors along with standard chemotherapy and radiation. It involves 30 adults with advanced head and neck cancer. The main goal is to check for side effects and see ho…

This Phase 3 trial is testing whether adding the targeted drug amivantamab to standard immunotherapy and chemotherapy can help people with advanced head and neck cancer live longer. About 500 participants who have not had prior treatment for their recurrent or metastatic cancer w…

This early-phase study tests a new drug called IMC-002 in about 62 adults with advanced solid tumors that no longer respond to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can help control the cancer. Participants receive t…

This early-stage study tests a chemotherapy drug (JNJ-1761981) that is injected directly into tumors in people with solid cancers that have not responded to standard treatments. The goal is to find a safe and effective dose, and to see if adding an immunotherapy (cetrelimab) help…

This early-phase study tests a new drug called GSK5533524, alone or with other cancer treatments, in adults with advanced solid tumors that have stopped responding to standard therapies. The main goals are to find a safe dose and see if the drug can shrink tumors or slow cancer g…

This phase 3 trial tests whether injecting NBTXR3 nanoparticles into tumors before radiation therapy can improve outcomes for elderly patients with advanced head and neck cancer who cannot receive chemotherapy. About 500 participants will be randomly assigned to receive either ra…

This early-phase study tests a new drug called BH3120, alone or with pembrolizumab, in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 245 p…

This study is testing the drug T-DXd (Enhertu) in 100 adults with advanced HER2-positive solid tumors who have already tried other treatments and have no good options left. The goal is to see how well the drug works in real-world settings, including how many patients respond and …

This early-phase study tests a virus (JNJ-87704916) that is injected directly into tumors to kill cancer cells. It is being tested alone and with another drug (cetrelimab) in people with advanced solid tumors who have run out of standard treatments. The main goals are to check sa…

Researchers are running a Phase 1 trial of IBI3001, an intravenous drug, in adults with unresectable, locally advanced or metastatic solid tumors. The study aims to find the highest dose people can tolerate and the dose to use in later trials. Participants receive IBI3001 by infu…

This early-phase trial tests a new drug called NEOK001 in people with advanced solid tumors that have stopped responding to standard treatments. NEOK001 is designed to deliver a cancer-killing agent directly to tumor cells by targeting two specific proteins. The study will first …

Researchers are testing an experimental drug called IBI3020 in adults with solid tumors that have spread or cannot be removed by surgery. IBI3020 is an antibody-drug conjugate that targets the CEACAM5 protein on tumor cells and delivers two different payloads. The main goals are …

This early-stage trial tests a new drug called KIVU-107 in 76 adults with advanced solid tumors that have not responded to standard treatments. KIVU-107 is an antibody-drug conjugate designed to target and kill cancer cells. The main goal is to find a safe dose and check for side…

This study tests whether a personalized, lower dose of radiation (guided by a special PET scan) works as well as the standard dose for people with HPV-positive throat cancer. About 291 participants will receive either the lower or standard radiation dose, along with standard chem…

This study tests an oral drug called NEO212 in people with specific brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control tumor growth. About 134 adults will take NEO212 alone or with sta…

This early-phase trial tests a new drug called CDR404 in up to 42 adults with advanced solid tumors that have a specific marker (MAGE-A4) and tissue type (HLA-A*02:01). The drug is designed to help the body's immune T-cells find and attack cancer cells. The main goals are to chec…

This early-stage trial is testing a new drug called MTI-301 in 42 adults with advanced solid cancers that have spread or can't be removed and haven't responded to standard treatments. The drug blocks an enzyme called SCD1, which some cancers use to grow and spread. The main goals…

This trial tests an experimental drug called ODM-216 in adults with advanced solid tumors, which are cancers that have spread or cannot be removed by surgery. The study has two parts: the first finds a safe dose, and the second checks how well that dose fights the cancer. Researc…

This early-stage study tests a new drug called DXC014 in about 150 people with advanced solid tumors, including small cell lung cancer, melanoma, and prostate cancer. The main goals are to check safety, find the right dose, and see if the drug shows any signs of shrinking tumors.…

This study tests a new drug called RC288 in people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to check safety, find the best dose, and see if it shrinks tumors. About 326 adults aged 18 to 75 with good overall health will take …

Researchers are testing an experimental biologic called AWT020 in adults with advanced solid tumors that have worsened after at least one standard treatment. The phase 1 trial gives AWT020 every three weeks at increasing dose levels to find the highest dose people can tolerate an…

Researchers are testing an experimental mRNA injection called ABO2011 in adults with advanced solid tumors that have worsened after standard treatment. The injection delivers genetic instructions for interleukin-12, a protein that can stir up an immune response, directly into the…

This early-stage trial tests an experimental drug called ACR-2316 in 100 people with advanced solid tumors that have spread or come back. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. It is for patients who have had up to 3 pr…

This early-stage trial tests an investigational drug called HP007, given as an injection directly into tumors, in adults with advanced solid tumors that have not responded to standard treatments or have come back. The main goals are to check the drug's safety, find the right dose…

This trial tests an experimental drug called FH-006 in 150 people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if FH-006 is safe, tolerable, and can shrink tumors. Researchers will measure how the drug moves through the body and …

This study offers long-term treatment with nivolumab and other cancer therapies to 1,500 patients who previously benefited from Bristol-Myers Squibb trials. The main goal is to monitor safety and side effects over time. Participants must have had a good response in their earlier …

This early-phase study tests a new drug called KIVU-305 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goal is to find a safe dose and see if the…

This early-phase trial is testing whether a nasal spray vaccine (WSK-IM05) combined with an immunotherapy drug (tislelizumab) can safely shrink HPV-positive throat tumors before surgery. Nine adults with newly diagnosed, resectable HPV-positive oropharyngeal cancer will receive t…

This early-phase study tests whether adding the experimental drug ipatasertib to standard chemotherapy and radiation is safe and effective for people with advanced head and neck cancer. Ipatasertib may help stop cancer cell growth. About 46 participants will receive the combinati…

The TAPUR study is testing a wide range of targeted cancer drugs in people with advanced solid tumors, lymphoma, or multiple myeloma whose tumors have specific genetic changes. The goal is to see if matching drugs to these genetic variants can shrink tumors or stop them from grow…

This study tests whether adding palbociclib to cetuximab helps people with a certain genetic type of head and neck cancer live longer than cetuximab alone. Participants must have HPV-unrelated cancer with a CDKN2A gene change that has worsened after prior immunotherapy. About 81 …

This early-stage trial is testing a new drug called lunresertib, alone or combined with two other experimental drugs (RP-3500 and Debio 0123), in people with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and check for earl…

This early-phase study tests a new drug called SLV-154 in about 70 people with advanced solid tumors (like head and neck, lung, breast, or ovarian cancer) that have spread. The main goal is to find a safe dose and check for side effects. Researchers will also watch for any signs …

This study tests a new treatment called VG2025, a modified herpes simplex virus designed to infect and kill cancer cells while also boosting the immune system. The trial enrolls adults with advanced solid tumors that have not responded to standard therapies and who have previousl…

This study tests a new drug called EIK1005, alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to other treatments. The goal is to find a safe dose and see if the drug shrinks tumors. About 160 adults with certain cancer types…

Researchers are testing an experimental drug called HG146 in people with adenoid cystic carcinoma that has come back or spread. The trial enrolls about 140 adults and gives them HG146 capsules to see if the drug can shrink tumors or slow cancer growth. Doctors track tumor respons…

This early-stage trial tests a new treatment called VLPONC-01, which is injected directly into head and neck tumors. It delivers a substance (IL-12) that may help the immune system attack the cancer. Some participants will also receive the immunotherapy drug pembrolizumab. The ma…

This early-phase trial tests the safety of CRD3874-SI, a drug that activates the STING pathway to boost the immune system against cancer. About 81 adults with advanced solid tumors (sarcoma, Merkel cell carcinoma, and others) will receive weekly IV infusions at increasing doses. …

Researchers compare two ways to manage the neck in people with early oral squamous cell carcinoma, a cancer that has not spread to lymph nodes. One group has surgery to remove the primary tumor only, then regular checkups with imaging to watch for lymph node spread. The other gro…

This early-phase study tests a new drug called BL-B01D1 in people with advanced lung cancer or other solid tumors that have spread or cannot be removed. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. About 470 adults will tak…

This study tests whether a combination of drugs (pembrolizumab and N-803, with or without special immune cells called PD-L1 t-haNK cells) can help shrink head and neck cancers before surgery. About 40 adults with untreated, HPV-negative head and neck cancer will receive these tre…

This early-phase trial is testing an oral drug called NP-101 in 35 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and side effects, with a secondary look at whether the drug can shrink tumors. Because it is a Pha…

This early-phase trial tests an experimental drug called HMPL-A580 in 186 adults with advanced or metastatic solid tumors that cannot be removed by surgery. The study aims to find a safe dose and check for early signs that the drug shrinks tumors. It is currently recruiting parti…

This early-stage trial tests whether a stool transplant (FMT) can help cancer patients who develop severe diarrhea or colon inflammation from immune-checkpoint inhibitor drugs. About 40 patients with various cancers will receive the transplant via colonoscopy. The main goal is to…

This early-phase trial is testing an experimental drug called BI-1808, alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced cancers like ovarian cancer, T-cell lymphoma, and melanoma. The main goals are to check safety, find the best dose, and see how…

This trial tests an experimental drug called ASP388B, given alone or alongside standard cancer therapies, in people with advanced solid tumors that have spread or cannot be removed by surgery. The study has two parts: the first finds a safe dose, and the second tests that dose in…

This Phase 1 trial tests D3L-002, a new drug that targets two immune checkpoints (TIGIT and PVRIG) to help the immune system fight cancer. It is for 24 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the r…

This early-phase trial is testing whether combining the drug talazoparib with one of three other drugs (palbociclib, axitinib, or crizotinib) can safely help control advanced solid tumors that have spread. Talazoparib blocks cancer cells from repairing their DNA, while the other …

This phase 2 trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy can shrink advanced squamous cell cancers of the nasal cavity and sinuses better than chemotherapy alone. About 35 adults with newly diagnosed, untreated stage II to IVb disease …

This early-stage trial is testing a new drug called DS3610a in about 70 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can help control the cancer. P…

This early-phase study is testing an experimental drug called YL217 in 220 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and look for early signs that the drug can shrink tumors. Participa…

This study tests a new drug, TER-2013, in people with advanced solid tumors (like breast, ovarian, or lung cancer) that have specific genetic changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and can shrink tumors. About 205 participants will receive th…

Researchers are running a first-in-human Phase 1 trial of HG381, an experimental drug given by intravenous injection, in adults with advanced solid tumors that have worsened after available treatments. The study aims to find out how safe and tolerable the drug is, how the body pr…

This trial tests whether a high-intensity interval training (HIIT) program can help head and neck cancer patients maintain or improve muscle mass after chemoradiotherapy. Researchers will use imaging and blood tests to see if changes in muscle and inflammation markers can predict…

This study tests a new drug called GI-108 in people with advanced or metastatic solid tumors, including lung, head and neck, pancreatic, and kidney cancers. The drug is designed to boost the immune system's ability to fight cancer. The trial will first find the safest dose, then …

This early-stage study tests a new drug called N-3C01, given alone or with an immunotherapy, in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety, find the right dose, and see if the combination shrinks tumors. About 114 a…

This early-phase trial is testing a new radioactive drug that seeks out a protein called Nectin-4 found on many cancer cells. The drug delivers a dose of radiation directly to the tumor, aiming to destroy it while sparing healthy tissue. About 150 adults with advanced bladder, br…

This phase III trial tests whether adding the immunotherapy drug serplulimab to standard induction chemotherapy can allow patients with advanced nasopharyngeal cancer to skip concurrent chemotherapy during radiation. The study plans to enroll 456 adults aged 18-65 with stage II-I…

This study compares two radiotherapy schedules for people with head and neck cancer who begin radiation more than 6 weeks after surgery. One group gets standard treatment (5 days a week), the other gets an accelerated schedule (6 days a week). The goal is to see if the faster sch…

This study tests a new drug called WJB001 combined with various chemotherapy drugs in people with advanced solid tumors that have not responded to standard treatments. The trial has three stages to find the safest dose, check how the body processes the drug, and see if it shrinks…

Researchers are testing an experimental injection called SHR-7787 in adults with advanced solid tumors that cannot be removed by surgery or have spread. The trial aims to find a safe dose, measure how the body processes the drug, and look for early signs that it shrinks tumors. P…

This phase 2 trial tests a new approach for patients with resectable head and neck squamous cell carcinoma. It combines an engineered mitochondrial vaccine (IMP3-Mito) with an immune checkpoint inhibitor (PD-1 inhibitor) given before and after surgery. The goal is to improve the …

This study tests a new treatment called iC9-CAR.CSPG4 T cells for people with head and neck cancer that has come back after standard treatments. The therapy uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells. The main goals are to fin…

This trial tests whether two imaging agents, Panitumumab-IRDye800 and [18F]NOTA-ABY-030, are safe and useful for helping surgeons identify head and neck tumors and cancer-containing lymph nodes during surgery. Adults with head and neck squamous cell carcinoma who are scheduled fo…

This early-stage trial tests a fluorescent dye attached to the cancer drug nivolumab. The dye is meant to make cancer cells glow during surgery, helping surgeons remove them more precisely. The study will enroll 40 people with head and neck cancer who are already scheduled for su…

Researchers are testing a PET/CT scan that uses a radioactive tracer called 68Ga-CAIX to detect solid tumors. The tracer binds to CAIX, a protein that many solid tumors produce when oxygen is scarce. The study enrolls about 100 adults with suspected or confirmed solid tumors, inc…

This study tests a new total-body PET scanner called the Biograph Vision Quadra to see if it can produce clearer images and find more tumors than standard PET/CT scanners. The study includes adults with non-small cell lung cancer, head and neck cancer, or prostate cancer who are …

Researchers at Washington University School of Medicine are studying whether a fluorescent dye called indocyanine green can help visualize the edges of head and neck squamous cell carcinoma during surgery. The study plans to enroll 25 adults who are having surgery for confirmed o…

This study tests a new radioactive tracer called 64Cu-DOTA-ECL1i that aims to make PET scans more accurate for head and neck cancer. Researchers will enroll 90 adults with newly diagnosed or recurrent/metastatic head and neck squamous cell carcinoma. The goal is to see if this tr…

This study is testing whether a special type of MRI (called DCE-MRI) can predict jaw bone damage (osteoradionecrosis) in head and neck cancer patients who have had radiation therapy. Researchers will scan up to 1,400 participants before, during, and after radiation to see if chan…

This early-stage study will test a new radioactive tracer called [89Zr]DFO-YS5 in 40 people with nerve sheath tumors, bladder cancer, or other advanced solid tumors. The tracer is designed to bind to cancer cells and show up on PET scans, potentially making tumors easier to see. …

Researchers in Zhongshan City, China, are studying whether blood and saliva markers linked to Epstein-Barr virus can detect nasopharyngeal cancer early. About 40,000 residents without a history of the cancer give samples that are tested for EBV antibodies and, in one group, EBV D…

Researchers are testing a radionuclide probe that targets PD-L1, a protein some tumors use to evade the immune system. Adults with solid tumors such as lung, cervical, breast, melanoma, or gastrointestinal cancers receive the probe and then undergo whole-body PET/CT imaging. The …

Researchers are testing a radioactive tracer called 18F-G1 that binds to granzyme B, a protein released when immune cells attack tumors. Adults with solid tumors or blood cancers who are about to start immunotherapy receive an injection of 18F-G1 and then undergo PET/CT scans. Th…

This study is testing whether a simple mouth rinse can detect HPV-related throat cancer early, before symptoms appear. Researchers will compare results from 200 people with throat cancer and 200 healthy volunteers matched by age, sex, and background. If accurate, this test could …

This study is testing two new blood tests designed to help doctors detect cancer in people who have symptoms that might be cancer. The study will involve 1,650 adults aged 45 and older who are already undergoing medical tests for possible cancer. The goal is to see how well these…

This phase 3 trial tests whether two different eye treatments can prevent vision loss in people who have had radiation therapy for a type of eye cancer called uveal melanoma. The study will compare faricimab injections given every 3 months, a fluocinolone acetonide implant placed…

Researchers at Vietnam National Cancer Hospital are testing whether adding one structured cognitive behavioral therapy (CBT) session to standard brief counseling helps cancer patients remain smoke-free. The trial enrolls 498 adults who smoked at cancer diagnosis and have stayed c…

This phase 3 trial tests an experimental drug called REGN7508 to prevent blood clots in people with solid tumors who are receiving cancer treatment. About 1,120 participants will receive either the drug or a placebo. The study measures how well the drug prevents clots and checks …

This phase 2 trial is testing an experimental drug called SIR2501 in adults with solid tumors who are about to receive paclitaxel-based chemotherapy. The goal is to see if SIR2501 is safe, tolerable, and might reduce the development of chemotherapy-induced peripheral neuropathy—a…

Researchers are testing whether giving antibiotics for 7 days after major surgery for mouth or throat cancer prevents wound infections better than the standard 24-hour course. The trial enrolls 80 adults scheduled for operations such as jaw or throat removal and tissue reconstruc…

People with head and neck cancer who have a tracheostomy and receive at least four weeks of radiation often develop severe skin reactions under the collar. This small study tests whether a silver-nylon dressing called Silverlon, already approved for radiation dermatitis, can prev…

Many people with advanced cancer take opioid pain medicines, which often cause constipation. This trial compares two laxatives, macrogol/electrolytes and magnesium hydroxide, to see which works better at preventing constipation when opioids are started. Adults with advanced cance…

Researchers are testing whether a high-intensity interval training (HIIT) program can slow immune aging and reduce the chance of cancer returning in people treated for head and neck cancer. The trial enrolls about 290 adults who have completed chemoradiotherapy. Participants do H…

Cancer patients with a central catheter can develop a blood clot in the upper arm. After at least three months of standard blood-thinning treatment, this trial tests whether switching to a lower, preventive dose of apixaban can stop new clots from forming. Participants stay on th…

This study tests whether regular phone check-ins and counseling can help people on oral cancer drugs feel better and avoid hospital visits. 600 patients will be assigned to symptom monitoring alone, or monitoring plus a self-help handbook and phone counseling for anxiety or sadne…

This study tests a special mental health program called DESCANSO/REST for Spanish-speaking Latino cancer patients who feel depressed, tired, or have trouble sleeping. The program is delivered through telehealth (video or phone calls). Researchers want to see if it is practical an…

This study tests a 6-week program called PAfitME that uses motion-controlled exergames (like Nintendo Switch) to help head and neck cancer survivors manage fatigue and pain after finishing treatment. 150 participants will be randomly assigned to either the exergaming program or a…

This study tests whether a short psychotherapy called brief behavioral activation (BBA) can reduce depression and anxiety and improve well-being in older adults who have survived cancer. BBA encourages people to set goals and engage in enjoyable or rewarding activities to change …

This study tests whether a supervised 12-week exercise and nutrition program in a community setting is practical and helpful for cancer survivors. About 150 participants, including survivors and their caregivers, will wear activity trackers, attend exercise sessions, and receive …

This study tests whether a special geriatric assessment (PGA) and tailored support can reduce side effects and improve quality of life for older adults (60+) undergoing radiation for head and neck cancer, and for their family caregivers. About 36 participants will receive either …

This pilot study tests two surgical methods—targeted muscle reinnervation (TMR) and regenerative peripheral nerve interfaces (RPNI)—alone and together to reduce chronic and phantom limb pain in cancer patients who have had an amputation. About 45 adults will be randomly assigned …

This Phase III trial tests whether American ginseng can reduce fatigue in 160 cancer patients. Fatigue is a common and tough side effect of cancer and its treatment. Participants will take either ginseng or a placebo, and researchers will measure changes in fatigue levels over ti…

This pilot study will give 20 early-stage cancer patients a preloaded cash card with $1,000 each month. The goal is to see if this simple cash support can prevent financial hardship, like debt or missed rent, and improve treatment outcomes. Researchers will measure how many peopl…

This phase 2 trial tests a dye called bevonescein that makes nerves glow during thyroid surgery, helping surgeons see and avoid them. Forty adults having thyroid removal will receive the dye before surgery. The main goal is to see if it improves voice outcomes by reducing nerve i…

Researchers at McMaster University are testing whether a structured exercise and education program helps people with cancer stay physically active during treatment. The trial enrolls 129 adults receiving cancer treatment of any type or stage. Participants join one of three groups…

This early-stage study tests a drug called resiniferatoxin (RTX), a chemical from a cactus-like plant similar to hot pepper, for people with severe cancer pain that standard treatments can't control. RTX is injected into the spine to destroy pain-transmitting nerves. The trial in…

This phase 3 trial tests whether megestrol acetate, a drug that stimulates appetite, can prevent weight loss in people with nasopharyngeal carcinoma undergoing chemoradiotherapy. Half of the 204 participants will take the drug daily for 11 weeks, and the other half will take a pl…

This study tests whether an AI-powered chatbot can help young adult cancer survivors manage ongoing symptoms like fatigue, anxiety, and sleep problems. Participants aged 18-39 who have finished primary cancer treatment will interact with the chatbot to get tailored educational su…

Researchers in China are observing how well the approved medicine HR20013 prevents nausea and vomiting caused by anticancer treatment. The study plans to follow about 3,000 adults with any tumor type who receive HR20013 as part of their usual care at more than 30 hospitals. It wi…

This trial explores whether inhaling essential oils like peppermint, lavender, or ginger can help reduce nausea and anxiety in cancer patients receiving chemotherapy infusions. Current anti-nausea drugs often cause constipation and fatigue, so researchers are looking for gentler …

Researchers are comparing two music-based programs to see which may better reduce anxiety in people with advanced cancer. One program pairs participants with a music therapist who uses an AI-powered platform to write songs together. The other has trained staff guide participants …

This study tests whether a single dose of psilocybin (the active ingredient in magic mushrooms) combined with talk therapy can reduce anxiety, depression, and existential distress in people with advanced cancer. Two hundred participants will receive either psilocybin or an active…

Researchers at Linkoeping University are co-designing a gamified AI medical yoga app with cancer patients and stakeholders, then testing how feasible and usable it is for home-based rehabilitation. Ten patients undergoing cancer treatment who speak Swedish will use the app for tw…

This phase 3 trial tests whether a lozenge called BupiZenge, which contains the long-acting painkiller bupivacaine, can relieve mouth pain from radiation therapy better than the standard lidocaine rinse. About 150 adults with head and neck cancer will be randomly assigned to one …

This Phase 2 trial tests whether using MRI to map saliva ducts before radiation therapy can reduce dry mouth in people with oropharyngeal cancer. About 98 participants will be randomly assigned to standard radiation planning or a new approach that spares the parotid ducts. The ma…

This study is testing a smartphone app called I-STAMP that helps people with advanced cancer keep track of their pain and medications. About 73 participants will use the app and rate how easy it is to use and how helpful it is. The goal is to see if the app can make managing canc…

This trial tests an educational program called A-PACT for people with solid tumors who are at high risk of decline. Trained lay health workers coach patients on how to discuss their care goals and end-of-life wishes with their medical team. The study will see if this reduces unpl…

Researchers are testing whether combining osteopathy, a hands-on physical therapy, with therapeutic hypnosis eases chronic pain and emotional distress in cancer patients better than osteopathy alone. The trial enrolls 80 adults with cancer who have had pain for at least three mon…

This trial tests an AI-powered avatar called ELISA that helps cancer patients learn about their treatment. Patients starting a new cancer therapy often struggle to remember complex information. The avatar provides personalized answers based on approved content. The study compares…

This study tests a program called ROCKS that helps people with advanced cancer and their family caregivers build optimism, communication skills, and knowledge to discuss advance care planning. 152 patient-caregiver pairs will be randomly assigned to the ROCKS program or usual car…

Researchers are developing and testing MybYte, a smartphone tool that offers personalised nutrition advice to teenagers aged 12 to 18 who are undergoing cancer treatment. In the first phase, about 15 teenagers help refine the tool through interviews and feedback. In the second ph…

This study tests an experimental drug called LY3537021 to see if it can better control nausea and vomiting caused by chemotherapy in adults with cancer. About 204 participants will receive either the drug or a placebo, and researchers will track who has no vomiting and does not n…

Researchers are testing whether adding a specialized radiation technique called spatially fractionated radiation therapy (SFRT) to standard palliative radiation helps people with large, inoperable solid tumors feel better. SFRT delivers high doses of radiation in a grid pattern, …

This trial tests whether a structured swallowing rehabilitation program can improve swallowing function, reduce jaw stiffness, and ease pain in people with head and neck cancer. Researchers will randomly assign 80 patients who have had radiation or chemoradiotherapy to either the…

This study tests a support program for Chinese cancer patients and survivors that includes education sessions, counseling, and peer support. The program is delivered by phone or video call. Researchers want to see if the program is practical and whether it improves quality of lif…

This study tests a website called Project Prepare that helps head and neck cancer patients stick with swallowing exercises and coping strategies during radiation therapy. The goal is to reduce long-term swallowing problems and improve quality of life. About 300 patients receiving…

This phase 4 trial compares two ways to manage pain after major surgery for head and neck cancer. Adults with oral, throat, or voice box cancers who are having tumor removal and complex reconstruction receive either standard fentanyl alone or fentanyl plus methadone during surger…

This pilot study tests a financial psycho-oncology program for cancer patients facing financial hardship. Participants attend six one-hour sessions over three months that combine emotional support with practical financial education. The study aims to see if the program is feasibl…

This study compares giving the cancer drug nivolumab (Opdivo) as a shot at home versus in a clinic for people with various advanced cancers. The goal is to see if home treatment improves patients' overall care experience and quality of life. About 50 adults will receive the drug …

This study tests whether cancer patients can complete a supervised exercise program from home using video calls. The program includes resistance training with dumbbells and aerobic exercise. Researchers want to see if this approach is practical and helps patients maintain functio…

This study tests a program called Contingency Management that gives Veterans rewards for quitting smoking, verified by breath tests. Researchers will first gather feedback from Veterans and staff, then run a small pilot with 20 Veterans over 5 weeks. If successful, a larger trial…

This study tests whether a high dose of gabapentin, a non-opioid pain medicine, can prevent the need for opioid painkillers in people with head and neck cancer who develop painful mouth sores from chemotherapy and radiation. About 228 participants will be randomly assigned to rec…

Researchers at Washington University School of Medicine are testing whether an online education and care navigation platform called CareOrbit helps patients prepare for and recover from head and neck cancer surgery. The study includes 50 adults scheduled for free flap surgery or …

This study compares giving cancer treatment at home versus in a clinic for 27 adults with various cancers in the Florida Panhandle. The goal is to see if home treatment is preferred and improves satisfaction, while also checking safety. Participants will receive their usual cance…

Chemotherapy often causes nausea and vomiting, which is especially hard for children. This study tests a new IV drug called NEPA (fosnetupitant/palonosetron) to prevent these side effects in kids with cancer. The trial has two parts: first, an open-label phase to find the right d…

This study tests whether a dietary supplement called Redsenol-1 Plus can safely reduce fatigue in adults who have had cancer treatment. 72 participants will take either the supplement or a placebo for 12 weeks. The main goal is to see if fatigue levels improve, as measured by a s…

This study looks at whether nerve transfer surgery can improve facial movement and quality of life for cancer patients who have facial paralysis after treatment. About 40 adults who are scheduled for this surgery will take part. Researchers will track side effects and measure cha…

This pilot study tests a spiritual care program called PEACE, led by chaplains and clinicians, for people with advanced cancer. The goal is to see if it helps patients whose faith influences their medical decisions. Sixty participants will receive two counseling sessions or usual…

This study tests a program called Focused Acceptance and Commitment Therapy (FACT) for advanced cancer patients who feel anxious about death. 70 participants will attend four weekly 35-45 minute sessions to learn coping skills. The goal is to see if FACT is safe, acceptable, and …

This study tests an 8-week virtual rehab program (CaRE@Home) for adults who finished cancer treatment for breast, colorectal, head and neck cancers, or lymphoma within the last two years. The goal is to see if the program reduces disability and improves physical function, anxiety…

This study tests whether a tailored coaching program can help adolescents and young adults (ages 15-24) with cancer take their oral medications as prescribed. Participants will work with a coach over four sessions to identify and overcome barriers to adherence, using an electroni…

This study tests a personalized program called SPOT-ON for cancer patients suffering from severe shortness of breath. Participants will receive a combination of breathing techniques, relaxation methods, posture adjustments, and oxygen-based therapies, either starting early or aft…

This study looks at whether teaching cancer patients about taste changes caused by chemotherapy and giving them self-management tools can help reduce those symptoms and maintain healthy eating. About 400 adults starting chemotherapy will be split into two groups: one gets standar…

This study tests a program called ICCAN that gives cancer patients extra help with social and economic needs, like finding resources and monthly check-ins. Researchers want to see if this support helps patients complete their cancer treatment and improves their quality of life, c…

Researchers at the University of Hong Kong are evaluating a survivorship program that sorts cancer patients into moderate or high needs after treatment. People with moderate needs receive weekly or bi-weekly e-intervention videos on managing distress and weight, with peer volunte…

This early study tests a new type of radiation therapy called ConformalFLASH, which delivers radiation at an ultra-high speed. It is for 10 adults with head and neck cancer who need a second round of radiation but cannot have surgery. The goal is to see if this fast treatment is …

This study tests whether a special light therapy (photobiomodulation) combined with a mobile health app can improve dry mouth and quality of life in people who have had head and neck cancer and completed radiation. Sixty participants will receive either real light therapy or a sh…

This study tests whether different types of massage can lower anxiety in cancer patients while they receive chemotherapy. Fifty adults who already have high anxiety and are at least one cycle into chemo will receive massage during their infusion sessions. Researchers will measure…

This study is testing whether a virtual, 8-session group therapy program can help cancer patients find meaning and reduce emotional distress. Researchers at MD Anderson Cancer Center will enroll 72 adults with a history of cancer. Participants will attend weekly 90-minute session…

This study looks at how the liver's immune system reacts to a chemotherapy drug called melphalan, given directly to the liver through a special procedure. It involves 10 adults with uveal melanoma that has spread to the liver. The goal is to understand immune changes, not to test…

This study follows 800 head and neck cancer patients who have had radiation therapy to see how often they develop blood vessel narrowing, strokes, or brain changes. Researchers will compare patients with nasopharyngeal cancer to those with other head and neck cancers. The goal is…

This study will follow 45 cancer patients who use cannabis, asking them to log their use in a smartphone app. Researchers want to learn how often and why patients use cannabis, what forms they use, and what effects they notice. The goal is to gather real-world data to guide futur…

This observational study looks at how having type 2 diabetes impacts quality of life in cancer patients receiving immunotherapy. Researchers will compare changes in well-being over six months between patients with and without diabetes. About 920 adults with solid tumors will fill…

This study looks at blood and saliva samples from 2000 people with cancer to find inherited genetic changes that may increase cancer risk, affect how tumors grow, or influence how well treatments work. Participants provide samples and allow researchers to analyze their DNA. The g…

This observational study follows people with head and neck squamous cell carcinoma who receive cisplatin-based chemoradiotherapy, comparing them with patients who receive radiotherapy alone. Participants undergo standardized hearing, tinnitus, and balance tests before, during, an…

This study looks at the best ways to invite American Indians from Southwestern tribes to take part in cancer genome sequencing. Researchers want to learn how genetic changes in cells lead to cancer and why these communities face higher cancer rates. The goal is to gather informat…

This study looks at how cancer patients view their doctor's compassion, communication, and professionalism when the doctor uses an electronic health record (EHR) during the visit. About 88 adults with cancer will watch videos or fill out questionnaires. The goal is to understand …

This study looks at how to set the breathing machine (jet ventilator) during a procedure that destroys tumors with heat or cold. The goal is to find the best air pressure setting to keep patients breathing well while the doctor works precisely. About 560 adults having tumor ablat…

This study tests a special microscope that takes live 3D images inside the eye during surgery. It aims to help surgeons see better when treating conditions like retinal detachment, macular holes, and cataracts. About 262 people will take part, including healthy volunteers and sur…

This pilot study is collecting real-world information from 100 cancer patients to better understand how treatments affect their quality of life and survival. Participants will fill out regular questionnaires about their well-being and undergo standard scans or lab tests every few…

This early-phase trial is testing whether injecting a fluorescently labeled version of the immunotherapy drug nivolumab directly into head and neck tumors is safe and helps visualize the tumor and nearby lymph nodes during surgery. Adults with head and neck squamous cell carcinom…

This study looks at whether a special health check-up done over video (telemedicine) can help find weak spots in older adults with cancer and guide their care. It includes 216 people aged 65 and older with cancer who are starting a new treatment. The goal is to see if this approa…

This study collects tissue samples from people with solid tumors who are already scheduled for surgery or biopsy at the NIH Clinical Center. Researchers will use the samples to study the biology of cancer and identify new targets for therapy. Up to 1,800 adults and children (age …

This study aims to learn how genes and the environment contribute to rare tumors and cancer risk in individuals and families. Researchers will collect medical histories, genetic samples, and health data from up to 500 participants of all ages. No treatment is given; the goal is t…

This study collects tissue and fluid samples from up to 5,000 cancer patients to help researchers learn more about cancer and develop new tests and treatments. Samples are taken from routine procedures or from extra biopsies done just for research. The goal is to build a resource…

This study is testing a program to help Native American cancer patients get better coordinated care. It brings together a cancer center and tribal health systems to improve communication and support. About 187 adults newly diagnosed with cancer will take part. The goal is to see …

This study is looking for 500 people with certain cancers (like eye or skin melanoma, kidney cancer, or mesothelioma) and their family members to understand how common BAP1 gene mutations are. Researchers will collect medical history and questionnaires to learn about cancer risks…

This study is following children and adults with olfactory neuroblastoma, a rare cancer of the nasal cavity, to learn more about how the disease behaves over time. Researchers will collect medical records, blood samples, and survey responses from 525 participants to track symptom…

This study tests a fertility preservation decision aid for young cancer survivors and their parents. The goal is to see if the tool helps them better understand fertility status and future parenthood options. About 358 participants will be randomly assigned to receive either the …

This study collects extra blood, urine, and tumor samples from children and adults with certain cancers to build a large tissue repository. Researchers will analyze these samples to learn more about the genetic and molecular makeup of these tumors. The goal is to support future s…

This study aims to create a large collection of tissue samples from people with head and neck disorders, such as hearing loss, mouth diseases, and throat cancers. Researchers will use leftover surgical tissue and additional samples like blood, saliva, and cheek swabs to study the…

This study enrolls adults with cancer or benign tumors who are already participating in other trials at the National Cancer Institute. Researchers will collect and link medical records and research samples from all of a patient's past, current, and future studies. The goal is to …

This study aims to find markers and causes of cancer by analyzing participants' DNA, RNA, and tissue samples. Researchers will use this information to improve cancer prevention, early detection, and treatment. The study will enroll 500 adults with cancer at Mayo Clinic.

This study follows about 700 cancer patients who have already received radiation therapy to understand the long-term side effects and how their disease progresses over time. No new treatments are given—researchers simply collect data from routine follow-up visits. The goal is to …

This large screening trial enrolls up to 2,900 people with advanced solid tumors that have spread or not responded to standard treatment. Researchers use genetic tests on tumor samples to find specific mutations, then assign patients to treatment trials testing drug combinations …

Researchers at the Medical College of Wisconsin run an observational registry for adults who receive care for a cancer-related condition. The registry collects medical data and biospecimens, both from past records and from samples given during the study. The goal is to study how …

Researchers are measuring the psychological and psychiatric health of adults with glioblastoma or head and neck cancer who are receiving radiotherapy. About 207 participants complete standardized questionnaires and clinician-rated assessments to track distress, mood, anxiety, res…

Radiation therapy for head and neck or pelvic cancers often irritates the skin, a condition called radiation-induced dermatitis. Researchers will follow 80 adults receiving radiation or combined chemotherapy and radiation, checking their skin weekly for five to seven weeks. The s…

This study looks at how the way medical information is presented influences treatment choices for people with advanced cancer. About 400 participants will fill out questionnaires and review made-up case scenarios. The goal is to learn how to better communicate health options to e…

This study looks at how a cancer drug called pelabresib changes the way the body processes three other medicines: repaglinide (for diabetes), midazolam (a sedative), and a birth control pill. It involves 24 adults with advanced cancers who have no standard treatment options. The …

Researchers are building multi-parameter models to predict how head and neck cancer patients fare after radiotherapy. The study follows 1000 patients who receive curative radiotherapy, either alone or with chemotherapy, and tracks survival, tumour control, treatment side effects …

This study collects samples from 320 people, including those with solid cancers (like lung, colon, or pancreatic cancer) and those undergoing lung cancer screening, to look for cancer cells and DNA in blood, urine, and bone marrow. The goal is to learn how cancer spreads and find…

This study is analyzing tumor and blood samples from 10,000 adults with advanced solid tumors or blood cancers to find genetic changes that can be targeted by existing drugs. The goal is to see how often these 'actionable' alterations occur and to guide patients toward personaliz…

This study aims to learn more about diseases that affect the salivary glands, which produce saliva. Researchers will collect medical data, blood, saliva, and tissue samples from people with these conditions, their relatives, and healthy volunteers. The goal is to better understan…

This study looks at whether special tests can predict which off-guideline drugs—FDA-approved for other cancers but not for a patient's specific cancer—might work for them. It involves 300 advanced cancer patients whose doctors are willing to try these drugs. The goal is to see ho…

Researchers are tracking 700 adults with solid tumors who are starting systemic anti-cancer treatment. The study measures body composition with bioimpedance and muscle performance with grip strength and chair-rise tests, plus activity trackers, to see whether sarcopenia predicts …

This study looks at how cancer and its treatments change a person's sense of taste and smell, and how that affects their eating and nutrition. Researchers will follow 306 people newly diagnosed with cancer of the mouth, throat, colon, or liver. They will use questionnaires, taste…

Researchers are building a large registry of genomic, molecular, and clinical information from people with suspected or confirmed cancer. Participants provide tumor sequencing data and allow the team to follow their treatment and outcomes over time. The goal is to discover gene a…

This study follows 300 people treated for sinonasal, nasopharyngeal, or skull base tumors to track their symptoms and functional changes over time. Participants will complete symptom questionnaires and undergo standard tests like hearing, eye, and speech exams. The goal is to lea…

This study looks at why people with head and neck cancer follow (or don't follow) swallowing exercises after radiation. Researchers will use blood tests and questionnaires to see if immune system proteins or feelings about the disease affect exercise habits. The goal is to find w…

This study is testing a new questionnaire called SOCS-OTS to see if it can correctly identify cancer survivors who need occupational therapy. Researchers at MD Anderson will compare it to a standard screening tool in 80 adults. The goal is to make sure the new tool accurately fin…

This study aims to understand why some cancer patients develop autoimmune side effects when treated with immune checkpoint inhibitors. Researchers will analyze blood cells and genetics from 600 participants to identify features linked to these side effects. The goal is to improve…

This study collects blood, tissue, and medical information from 240 cancer patients who have had serious side effects from immunotherapy. The goal is to store these samples in a national biorepository for future research. By studying these samples, scientists hope to better predi…

This study tests whether a digital chatbot can help more adolescents and young adults (AYA) with cancer get genetic counseling and testing compared to standard remote services. About 535 participants aged 18-39 will use either a chatbot or standard telehealth. The goal is to see …

This study collects blood and tissue samples from 2000 people—some with cancer and some without—to create a blinded reference set. Researchers will use these samples to evaluate how well new blood tests can detect many types of cancer early. The goal is to improve the accuracy of…

This study explores the link between physical activity and thinking skills in people who survived cancer as adolescents or young adults. Researchers will use computer-based brain games to measure memory and attention. The goal is to understand how exercise might help brain health…

Researchers are collecting weekly urine samples from adults with solid tumor cancers to look for metabolic changes that occur as death approaches. The study aims to understand the biology of dying and explore whether a test could one day predict the last days or weeks of life. Be…

This study enrolls 275 people with advanced solid tumors to test a new approach: using a rapid, detailed analysis of each patient's tumor and immune system to guide treatment choices. The goal is to improve the success rate of immunotherapy, which currently helps only 20-30% of p…

This study will follow 6,000 children, adolescents, and young adults with cancer in low- and middle-income countries. Researchers will collect data from medical records and questionnaires to understand why treatment failure and severe side effects are more common in these setting…

This study aims to safely collect health information like heart rate and activity levels from cancer patients using devices like smartphones and wearables. Researchers will use this data to learn more about how it relates to cancer diagnosis, treatment response, and risk factors.…

This study is collecting information from up to 40,000 cancer patients who are receiving radiation therapy. Researchers will track their outcomes to better understand what works and how to reduce side effects. The goal is to improve patient care by learning from real-world treatm…

This study looks at how people with advanced cancer feel about stopping or reducing medications that may no longer help. Researchers will interview about 25 patients and survey 300 more to understand their attitudes and beliefs. The goal is to learn what factors influence their v…

This observational study collects tumor tissue and blood cells from 200 people with advanced solid tumors like colorectal, lung, and pancreatic cancers. The goal is to understand how often tumors lose a specific marker (HLA) and to store participants' own T cells for potential fu…

This study tests a new chatbot designed to help cancer patients and their caregivers in rural areas find clear information about insurance, travel costs, and other financial aspects of cancer care. About 60 participants will be randomly assigned to use either a hybrid chatbot or …

This observational study is looking at whether certain markers in the blood can predict immune-related side effects in cancer patients receiving immunotherapy. Researchers will collect blood samples and health data from 200 participants during routine visits. The goal is to bette…

This study aims to create a large collection of blood samples from 2,500 people with or at high risk for cancer. Researchers will use these samples to study liquid biopsies, which are blood tests that may help detect cancer, track treatment response, and spot recurrence. Particip…

This study looks at the genes in cancer tumors to find mutations that might be important for how the cancer grows. Researchers will use leftover tissue from surgeries or biopsies, along with a blood or saliva sample, to compare cancer genes to normal genes. The goal is to underst…

This study uses advanced 4D MRI scans to measure blood flow and heart function in adults with heart disease or cancer. Researchers aim to see if these detailed images can help predict how these diseases will progress. The study involves 1,000 participants who are already schedule…

This study is testing whether wearable activity trackers like Fitbits and iPhones can help predict when cancer patients undergoing radiation therapy might need emergency care or hospitalization. Researchers will collect step counts and other health data from 260 participants to b…

This study will test a remote monitoring platform designed to help cancer patients who face barriers like language or lack of insurance. About 50 adults with cancer will use the platform at home to track symptoms and communicate with their care team. The goal is to see if the pla…

Researchers are studying whether body mass index (BMI) is linked to health-related quality of life in people with solid tumors. The trial includes about 1,380 adults with a confirmed solid tumor diagnosis. Participants complete standard quality-of-life questionnaires, and researc…

This study is testing whether adding a short MRI scan before surgery can help predict if all cancer will be removed during transoral robotic surgery (TORS) for HPV-positive tonsil cancer. About 30 adults will get a standard MRI with two extra sequences that take only 6 minutes. D…

Researchers at Mayo Clinic are studying whether an implantable Doppler monitor can record the sound of blood flowing through a free flap and convert it into a visual signal. The trial enrolls 100 adults scheduled for free flap surgery, a procedure that moves tissue to rebuild par…

This study follows over 1,500 children and adults who previously received gene-modified T cell therapy for cancer. Researchers will track side effects, how long the modified cells last, and overall survival for up to 15 years. No new treatment is given—the goal is to understand l…

This early-phase study is testing the cancer drug pelabresib in 24 people with advanced cancers who also have liver problems. The goal is to see how the liver affects the drug levels in the body. Participants will take the drug daily for 14 days, then have a week off. This resear…

This study interviews cancer care providers, patients, and caregivers to learn their thoughts and feelings about receiving hospital-level care at home. The goal is to understand what people know and believe about home hospital care, so that future programs can be designed to bett…

This is a Phase 1b, 2-part, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of \[64Cu\]Cu-AKY-2519 and/or \[225Ac\]Ac-AKY-2519, as well as the preliminary anti-tumor activity of \[225Ac\]Ac-AKY-2519 in participants with B7…

The goal of this study is to evaluate the efficacy and safety of Ivonescimab in participants with advanced, metastatic salivary gland cancers. The name of the study drug involved in this study is: -Ivonescimab (a type of antibody)